Table 4.
Common sites of metastatic mucosal melanoma detected by imaging studies during the course of disease from diagnosis to death or end of follow-up period compared with cutaneous melanoma
| Site | Anal (n = 3) | Rectal (n = 4) | Vaginal (n = 7) | Sinonasal (n = 4) | Total (n = 18) | Cutaneous melanoma, %a |
|---|---|---|---|---|---|---|
| Lung, n (%) | 2 (66) | 4 (100) | 7 (100) | 3 (75) | 16 (89) | 18–36 |
| Liver, n (%) | 1 (33) | 3 (75) | 4 (57) | 4 (100) | 12 (67) | 14–20 |
| Peritoneum, n (%) | 1 (33) | 2 (50) | 3 (43) | 2 (50) | 8 (44) | N/A |
| CNS, n (%) | 1 (33) | 2 (50) | 2 (29) | 0 (0) | 5 (28) | 2–20 |
| Bone, n (%) | 1 (33) | 1 (25) | 0 (0) | 1 (25) | 3 (16) | 4–17 |
| Skin and subcutaneous, n (%) | 1 (33) | 1 (25) | 0 (0) | 1 (25) | 3 (16) | 37–59 |
| Gastrointestinal tract, n (%) | 0 (0) | 1 (25) | 0 (0) | 1 (25) | 2 (11) | 1–8 |
aFrom Leiter et al.[15]. These figures represent sites of metastatic cutaneous melanoma detected by clinical and imaging techniques. Autopsy-detected metastatic sites are not included.